ISRCTN43344383 https://doi.org/10.1186/ISRCTN43344383

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

Submission date	Recruitment status	[ ] Prospectively registered
19/08/2002	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
19/08/2002	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
11/01/2019	Cancer	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
LK/FIL

Study information

Scientific Title
A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Leukaemia (acute), Leukaemia (chronic)

Interventions
1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products
2. Arm B: Patients receive Pall filtered blood or platelet donations

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Leukocyte-Depleted Red Cell and Platelet Donations

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1990

Completion date
01/04/1992

Eligibility

Key inclusion criteria
1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma
2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible
3. Any age
4. Fit to undergo the treatments as defined in protocol

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1990

Date of final enrolment
01/04/1992

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Pall Biomedical Ltd (UK)

Sponsor details
Europa House
Havant Street
Portsmouth
United Kingdom
PO1 3PD

Sponsor type
Industry

Website
http://www.pall.com/

ROR
https://ror.org/04hw9y579

Funder(s)

Funder type
Industry

Funder Name
Pall Biomedical Ltd (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration